Redmile Group, LLC Nurix Therapeutics, Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q3 2024

A detailed history of Redmile Group, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 4,280,981 shares of NRIX stock, worth $94.4 Million. This represents 6.28% of its overall portfolio holdings.

Number of Shares

4,280,981

Previous 4,423,616 3.22%

Holding current value

$94.4 Million

Previous $92.3 Million 4.1%

% of portfolio

6.28%

Previous 6.02%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$18.93 - $25.69 $2.7 Million - $3.66 Million	-142,635 Reduced 3.22%	4,280,981 $96.1 Million
Q2 2024 Aug 14, 2024	SELL	$12.02 - $21.3 $713,988 - $1.27 Million	-59,400 Reduced 1.33%	4,423,616 $92.3 Million
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $9.53 Million - $19.2 Million	1,226,497 Added 37.66%	4,483,016 $65.9 Million
Q4 2023 Feb 14, 2024	BUY	$4.25 - $10.71 $1.7 Million - $4.28 Million	399,210 Added 13.97%	3,256,519 $33.6 Million
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $938,947 - $1.43 Million	107,925 Added 3.93%	2,857,309 $28.5 Million
Q1 2023 May 15, 2023	SELL	$8.56 - $13.26 $2.15 Million - $3.33 Million	-251,400 Reduced 8.38%	2,749,384 $24.4 Million
Q4 2022 Feb 14, 2023	SELL	$9.86 - $14.59 $58,174 - $86,081	-5,900 Reduced 0.2%	3,000,784 $32.9 Million
Q2 2022 Aug 15, 2022	SELL	$7.88 - $14.82 $95,348 - $179,322	-12,100 Reduced 0.4%	3,006,684 $38.1 Million
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $782,870 - $1.79 Million	60,500 Added 2.05%	3,018,784 $42.3 Million
Q4 2021 Feb 14, 2022	SELL	$26.43 - $34.5 $3.56 Million - $4.65 Million	-134,793 Reduced 4.36%	2,958,284 $85.6 Million
Q3 2021 Nov 15, 2021	SELL	$22.71 - $36.69 $2.2 Million - $3.56 Million	-97,000 Reduced 3.04%	3,093,077 $92.7 Million
Q2 2021 Aug 16, 2021	SELL	$24.21 - $35.89 $3 Million - $4.45 Million	-124,040 Reduced 3.74%	3,190,077 $84.6 Million
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $12.6 Million - $23.5 Million	467,992 Added 16.44%	3,314,117 $103 Million
Q4 2020 Feb 16, 2021	BUY	$22.85 - $48.44 $5.77 Million - $12.2 Million	252,555 Added 9.74%	2,846,125 $93.6 Million
Q3 2020 Nov 16, 2020	BUY	$16.05 - $34.91 $41.6 Million - $90.5 Million	2,593,570 New	2,593,570 $90.5 Million

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Nurix Therapeutics, Inc. Transaction History